Skip to main content

Advertisement

Log in

New drugs in the therapy of neuroendocrine tumors

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Neuroendocrine tumors (NET) are a rare and heterogeneous group of neoplasms of a relatively indolent nature whose incidence and prevalence are increasing. Despite the advances made in the field of NET over the past years, these tumors eventually progress to metastatic disease in most of the patients, with a fatal outcome in the majority. Traditional cytotoxic agents remain of limited efficacy; however, recently, a better understanding of molecular pathways has provided clues to potential molecular targets for new therapeutic strategies. Somatostatin analogs are well known to be useful for the control of symptoms in functioning tumors, and it was recently demonstrated that they can inhibit tumor progression in certain disease settings. Moreover, the recently published randomized trials with the multi-TKI sunitinib and with the mTOR-inhibitor everolimus have demonstrated, for the first time, their ability to positively impact the natural history of pancreatic NET (PNET). In this short review, we will discuss available data on newer molecular targeted agents for the treatment of advanced well-differentiated gastro-entero-pancreatic NET (GEP-NET). A possible algorithm for the use of these treatments in the context of the extreme heterogeneity of GEP-NET presentation will be proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999, 10(Suppl 2): S31–8.

    Article  PubMed  Google Scholar 

  2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97: 934–59.

    Article  PubMed  Google Scholar 

  3. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451: 757–62.

    Article  PubMed  CAS  Google Scholar 

  4. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori 2010, 96: 806–9.

    PubMed  Google Scholar 

  5. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003, 10: 451–8.

    Article  PubMed  Google Scholar 

  6. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32: 133–8.

    Article  PubMed  CAS  Google Scholar 

  7. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8: 299–309.

    Article  PubMed  CAS  Google Scholar 

  8. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008, 15: 701–20.

    Article  PubMed  CAS  Google Scholar 

  9. Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005, 18: 1329–35.

    Article  PubMed  CAS  Google Scholar 

  10. Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003, 89: 1766–75.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004, 136: 1297–302.

    Article  PubMed  Google Scholar 

  12. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16: 525–37.

    Article  PubMed  CAS  Google Scholar 

  13. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990, 39(Suppl 2): 63–9.

    Article  PubMed  CAS  Google Scholar 

  14. Rinke A, Müller HH, Schade-Brittinger C, et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27: 4656–63.

    Article  PubMed  CAS  Google Scholar 

  15. Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 2012, 24: 282–93.

    Article  CAS  Google Scholar 

  16. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24: 7455–64.

    Article  PubMed  CAS  Google Scholar 

  17. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18: 1926–45.

    Article  PubMed  CAS  Google Scholar 

  18. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008, 87: 168–81.

    Article  PubMed  CAS  Google Scholar 

  19. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26: 4311–8.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28: 69–76.

    Article  PubMed  CAS  Google Scholar 

  21. Yao JC, Shah MH, Ito T, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364: 514–23.

    Article  PubMed  CAS  Google Scholar 

  22. Pavel ME, Hainsworth JD, Baudin E, et al; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378: 2005–12.

    Article  PubMed  CAS  Google Scholar 

  23. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009, 360: 195–7.

    Article  PubMed  CAS  Google Scholar 

  24. Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011, 16: 783–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas-Palomar L, Sánchez-Juan C. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract 2011, 17: e17–20.

    Article  PubMed  Google Scholar 

  26. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95: 1148–54.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  27. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24: 401–6.

    Article  PubMed  CAS  Google Scholar 

  28. Gross DJ, Munter G, Bitan M, et al; Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006, 13: 535–40.

    Article  PubMed  CAS  Google Scholar 

  29. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26: 1316–23.

    Article  PubMed  CAS  Google Scholar 

  30. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2007, 25 (Suppl): 4504 (abstract).

    Article  Google Scholar 

  31. Castellano DE, Capdevila J, Salazar R, et al; Spanish Neuroendocrine Tumor Group (GETNE). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 2011, 29 (Suppl): 4113 (abstract).

    Article  CAS  Google Scholar 

  32. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26: 3403–10.

    Article  PubMed  CAS  Google Scholar 

  33. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364: 501–13.

    Article  PubMed  CAS  Google Scholar 

  34. Phan AT, Yao JC, Fogelman DR, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010, 28 (Suppl): 4001 (abstract).

    Article  Google Scholar 

  35. Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006, 84: 42–8.

    Article  PubMed  CAS  Google Scholar 

  36. Hobday TJ, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2006, 24 (Suppl): 4043 (abstract).

    Article  Google Scholar 

  37. Reidy DL, Hollywood E, Segal M, Saltz L. A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1 R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). J Clin Oncol 2010, 28 (Suppl): 4163 (abstract).

    Article  CAS  Google Scholar 

  38. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011, 18: 127–37.

    PubMed  Google Scholar 

  39. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22: 4762–71.

    Article  PubMed  CAS  Google Scholar 

  40. Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010, 102: 1106–12.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  41. Delaunoit T, Ducreux M, Boige V, et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 2004, 40: 515–20.

    Article  PubMed  CAS  Google Scholar 

  42. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117: 268–75.

    Article  PubMed  CAS  Google Scholar 

  43. Eriksson B, Annibale B, Bajetta E, et al; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009, 90: 214–9.

    Article  PubMed  CAS  Google Scholar 

  44. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13: 2986–91.

    Article  PubMed  CAS  Google Scholar 

  45. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011, 117: 4617–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Grozinsky-Glasberg MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grozinsky-Glasberg, S., Gross, D.J. New drugs in the therapy of neuroendocrine tumors. J Endocrinol Invest 35, 930–936 (2012). https://doi.org/10.3275/8651

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8651

Key-words

Navigation